Postoperative Delirium
Conditions
Interventions
Liraglutide Group:Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for t
Vehicle Group:Subcutaneous injection of vehicle: the same volume as liraglutide administrated at the corresponding times.
Sponsors
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age = 60 years 2. Type 2 diabetes 3. Patients undergoing elective cardiac surgery
Exclusion criteria
Exclusion criteria: 1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc 2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments 3. History of central nervous system damage or surgery 4. Cardiac function NYHA Class IV 5. Severe liver dysfunction (Child-Pugh Class C) 6. Severe renal failure requiring renal replacement therapy 7. History of pancreatitis 8. Type 1 diabetes 9. Patients whose blood sugar cannot be controlled within 4-8 mmol/L during the intervention period 10. Patients with medullary thyroid carcinoma or a family history of it 11. Pregnant or breastfeeding women 12. Intolerance or allergy to liraglutide 13. Previous use of GLP-1A and SGLT2i 14. Patients who refuse to sign the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of delirium within 7 days postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of delirium within 7 days postoperatively;Cognitive function at discharge, and at 3 months, 6 months, and 1 year postoperatively;Anxiety and depression at discharge, and at 3 months, 6 months, and 1 year postoperatively;Cardiac function at discharge, and at 3 months, 6 months, and 1 year postoperatively;Duration of ICU stay;Mechanical ventilation time;Duration of hospital stay ; In-hospital mortality;Incidence of adverse events during medication use;Rate of major cardiovascular adverse events within 1 year post-surgery (including cardiovascular death, myocardial infarction, and stroke);Serum levels of NSE;Serum levels of CRP;Serum levels of IL-1a;Serum levels of TNF-a;Serum levels of C3;Serum levels of LDH;Serum levels of CK;Serum levels of BNP;Serum levels of CK-MB;Serum levels of AST;Serum levels of cTNT;Serum levels of C1q;Serum levels of IL-1ß;Serum levels of IL-6;Serum levels of S100ß; | — |
Countries
China
Contacts
Public ContactWenxue Liu
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Outcome results
None listed